Europe Biomarker Technologies Market to Witness Rapid Growth through 2025
Rise in cases of infectious & autoimmune diseases and
availability of advanced healthcare facilities to drive Europe biomarker
technologies market
According to
TechSci Research report, “Europe Biomarker Technologies Market By Test Type (Solid
Biopsy, Liquid Biopsy), By Technology (Immunoassay, DDPCR, Next Generation
Sequencing (NGS), Mass Spectrometry, DHPLC, Others), By Product (Consumables,
Instruments, Services, Software/Informatics), By Indication (Oncology,
Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, Others),
By End User (Pharmaceutical Companies, Hospitals, CROs, Diagnostic Labs,
Research Institutes), By Application (Clinical Diagnostics, Research, Drug
Discovery & Development), By Country, Forecast & Opportunities, 2025”, the market is expected to witness robust growth during the
forecast period owing to rise in cases of infectious and autoimmune diseases
including COVID-19. The increasing uses of biomarker technology in cancer
treatment is also acting as major growth driver for the market. In addition to
this, extensive R&D activities in healthcare sector coupled with rising adoption
of early toxicity testing are anticipated to provide huge growth opportunities
for Europe biomarker technologies market through 2025. Also, the various
advantages of biomarker technologies are leading to their increased adoption in
drug development and genome mapping programs, which is further supporting the
market growth.
Additionally, rise in healthcare expenditure and
growing requirement for personalized medicines are augmenting the growth of
Europe biomarker technologies market. Furthermore, the market is also expanding
owing to growing prevalence of cardiovascular and neurological disorders in
various European countries. Various governments are also promoting biomarker
technologies by increasing funding for biomarker research. Also, the advancements
in medical sector are promoting the growth of biomarker technologies market.
However, biomarker discovery requires high initial capital investment which might
limit the market growth.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Europe Biomarker Technologies Market"
https://www.techsciresearch.com/report/europe-biomarker-technologies-market/5101.html
Europe biomarker technologies market is segmented based on test type,
technology, product, indication, end user, application and country. Based on
product the market can be segmented into consumables, instruments, services and
software/informatics. Among them, consumables segment accounted for largest
market share in 2019 and is further expected to dominate the market during the
forecast period as they are vital part of biomarker testing and are essential
for performing various technologies.
Based on
technology, Europe biomarker technologies market can be categorized into immunoassay,
DDPCR, Next Generation Sequencing (NGS), mass spectrometry, DHPLC and others.
Among them, the Next Generation Sequencing (NGS) technology is expected to register
fastest CAGR through 2025 due to surge in research related to oncology and
increasing uses of NGS technology in examining difference between various cancer
forms that otherwise seem identical.
Major players operating in the Europe
biomarker technologies market include F. Hoffmann-La Roche AG, Merck KGAA,
Beckman Coulter, Inc., Qiagen N.V., Biomérieux SA, Bio-Rad Laboratories N.V.,
Siemens AG, Abbott Laboratories, QIAGEN and Danaher Corporation. The market
players are involved in growth strategies such as mergers & acquisitions
and product innovation to strengthen their market position.
Download
Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=5101
Customers can
also request for 10% free customization on this report.
“The availability
of advanced treatment facilities and good healthcare infrastructure is making
Europe a lucrative market for biomarker technologies. Moreover, the increasing requirement
for efficient and accurate diagnosis is supporting the growth of Europe
biomarker technologies market. With the entry of new players, Europe biomarker
technologies market is expected to witness rapid growth in coming years,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Europe Biomarker Technologies Market By Test
Type (Solid Biopsy, Liquid Biopsy), By Technology (Immunoassay, DDPCR, Next
Generation Sequencing (NGS), Mass Spectrometry, DHPLC, Others), By Product
(Consumables, Instruments, Services, Software/Informatics), By Indication
(Oncology, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders,
Others), By End User (Pharmaceutical Companies, Hospitals, CROs, Diagnostic
Labs, Research Institutes), By Application (Clinical Diagnostics, Research,
Drug Discovery & Development), By Country, Forecast & Opportunities,
2025” has evaluated
the future growth potential of Europe biomarker technologies market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in Europe biomarker technologies market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]